Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Publication Date: September 22, 2024
Company Overview
Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company headquartered in Tarrytown, New York, dedicated to discovering, developing, and commercializing innovative medicines for various diseases worldwide. Since its founding in 1988, Regeneron has made significant strides in the healthcare sector, particularly in the treatment of conditions related to ophthalmology, dermatology, and asthma, with flagship products like EYLEA and Dupixent. The company is also actively pursuing therapies for cancer, cardiovascular diseases, and infectious diseases, making it a formidable player in the biotechnology landscape. As of now, REGN is publicly traded and shows strong signs of market resilience and growth potential.
Investment Outlook
In the current dynamic environment of the biotechnology industry, Regeneron Pharmaceuticals presents a favorable buy rating for investors looking to enter or expand their portfolios in this sector. The stock is currently priced at $1,145.03, with an encouraging target high of $1,300, signaling substantial upside potential. Analysts have established a target mean price of $1,176.79, which supports expectations of positive price movement in the near term. Financially, Regeneron boasts a total revenue of approximately $13.49 billion, underscoring its market strength. Furthermore, the low short interest, with only 0.0201% of shares held short, suggests a positive investor sentiment and limited bearish positioning against the stock.
Market Performance Insights
Regeneron Pharmaceuticals’ stock has demonstrated resilience with a recent trading price of $1,145.03, slightly above its fifty-day average of $1,130.05. This performance indicates a positive short-term trend diverging from longer-term averages. Over the past year, REGN’s stock has seen considerable volatility, peaking at $1,211.20 and dipping to a low of $769.19. This fluctuation indicates potential investment opportunities for those willing to navigate the market’s ups and downs. Overall, with a consensus buy rating from 24 analysts and a mean recommendation score of 2.0, Regeneron Pharmaceuticals stands out as an attractive investment option within the biopharmaceutical sector.
| Metric | Value |
|---|---|
| Market Cap | $126.2b |
| Total Debt | $2.7b |
| Total Cash | $9.8b |
| Shares Outstanding | 108.4m |
| Float Shares | 103.4m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.